Showing results (51-60 of 79) with videos related to

Sort By:
Pageof 8
Journal of Clinical Apheresis|November 15, 2017
Neutropenic fever during peripheral blood progenitor cell mobilization is associated with decreased CD34+ cell collection and increased apheresis collection daysJack Khouri, Lisa Rybicki, Navneet Majhail, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 28, 2014
Synergistic effect of major histocompatibility complex class I-related chain a and human leukocyte antigen-DPB1 mismatches in association with acute graft-versus-host disease after unrelated donor hematopoietic stem cell transplantationMedhat Askar, Yuchu Sun, Lisa Rybicki, et al.
British Journal of Haematology|March 18, 2011
Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centresStephen D Smith, Craig H Moskowitz, Robert Dean, et al.
British Journal of Haematology|October 14, 2009
Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposideRobert M Dean, Brad Pohlman, John W Sweetenham, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|November 14, 2007
Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapyDita Gratzinger, Shuchun Zhao, Robert J Tibshirani, et al.
Hematology/Oncology and Stem Cell Therapy|December 10, 2020
Survival following relapse after allogeneic hematopoietic cell transplantation for acute leukemia and myelodysplastic syndromes in the contemporary eraSanghee Hong, Lisa Rybicki, Donna Corrigan, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 26, 2016
Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times-Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell TransplantationBrian T Hill, Lisa Rybicki, Kelley D Carlstrom, et al.
Leukemia & Lymphoma|December 30, 2020
Outcomes and factors impacting use of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma: results from an intention-to-treat analysisAgrima Mian, Wei Wei, Allison M Winter, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2019
Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell LymphomaJessica El-Asmar, Lisa Rybicki, Brian J Bolwell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 21, 2016
Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple MyelomaSanghee Hong, Lisa Rybicki, Donna Abounader, et al.
Pageof 8